Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 7.57B |
| Revenue (ttm) | 1.40B |
| Net Income (ttm) | 316.89M |
| Shares Out | 118.47M |
| EPS (ttm) | 2.56 |
| PE Ratio | 24.95 |
| Forward PE | 7.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,310,880 |
| Open | 65.27 |
| Previous Close | 64.49 |
| Day's Range | 62.60 - 65.28 |
| 52-Week Range | 47.50 - 82.22 |
| Beta | 1.03 |
| Analysts | Buy |
| Price Target | 78.18 (+22.42%) |
| Earnings Date | May 5, 2026 |
About HALO
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) admini... [Read more]
Financial Performance
In 2025, Halozyme Therapeutics's revenue was $1.40 billion, an increase of 37.55% compared to the previous year's $1.02 billion. Earnings were $316.89 million, a decrease of -28.64%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $78.18, which is an increase of 22.42% from the latest price.
News
Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology
SAN DIEGO, April 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a g...
Halozyme Appoints David Ramsay as Interim Chief Financial Officer
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today announced that David Ramsay has been appointed Interim Chief Financial Officer ...
Halozyme Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Revenue is projected to grow 22%–30% in 2024, driven by royalties from key SubQ products and new launches. Pipeline expansion, strategic acquisitions, and new partnerships are expected to sustain growth into the 2030s and 2040s, with Hypercon projected to generate $1 billion in royalties by the mid-2030s.
Halozyme Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Recent acquisitions and technology advances are expanding the pipeline and enabling entry into small-volume, at-home subcutaneous drug delivery. Strong financial growth, disciplined M&A, and robust partner interest support a doubling of commercialized and development products by 2028.
U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
FDA approval based on Phase 3 data demonstrating statistically significant improvements in progression ‑free survival and overall survival versus standard of care regimens SAN DIEGO, March 6, 2026 /PR...
Halozyme Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Recent acquisitions and new ENHANZE deals are driving expansion into subcutaneous drug delivery, with HyperCon assets poised for rapid growth and significant royalty potential. Patent extensions and minimal Medicare exposure support long-term revenue durability, while innovation in delivery formats accelerates adoption across major therapies.
Halozyme to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, is scheduled to present a...
Halozyme Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 results with 38% revenue growth, major portfolio expansion, and strong royalty gains from ENHANZE-enabled products. 2026 guidance projects 22%–30% revenue growth, new clinical programs, and continued strategic acquisitions.
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billion Full Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million Completed Acquisitions of Elektrofi's Hypercon™ Technolo...
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results
SAN DIEGO, Feb. 10, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2025 financial and operating results o...
Halozyme Therapeutics Transcript: Investor update
Acquisitions of Elektrofi and Surf Bio expand the subcutaneous delivery portfolio, driving strong projected revenue and royalty growth through 2028. ENHANZE, Hypercon, and Surf Bio technologies position the company for durable, high-margin growth, with new partnerships and streamlined clinical development accelerating future launches.
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
Updates Preliminary Unaudited 2025 Estimates: - Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1 - Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1 Raises 2026 Fin...
Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update
SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will host an Investor Conference Call on Wednesday, January 28, 2026, at 5:30 am PT ...
Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE®
Agreement provides Takeda with exclusive access to ENHANZE® drug delivery technology for vedolizumab SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) today announced ...
Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity
Agreement supports development and commercialization of higher-dose, subcutaneous administration strategies for nimacimab SAN DIEGO, Jan. 5, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: H...
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
RYBREVANT FASPRO™ is approved across all indications of RYBREVANT® (amivantamab-vmjw) SAN DIEGO , Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced th...
Jim Lang Elected to Halozyme's Board of Directors
SAN DIEGO , Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the election of Jim Lang to its Board of Directors. Mr. Lang brings more than 30 year...
Halozyme Granted Injunction Against Merck & Co. in Germany in Keytruda Patent Case
The Munich Regional Court ruled there was imminent infringement for Merck & Co.'s Keytruda SC in Germany related to Halozyme's MDASE patents in Europe, the San Diego company said.
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme), announced today that a German court has granted its request for a preliminary injunction ordering Merck ...
Halozyme Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Strong adoption of subQ delivery technologies and blockbuster products drive robust revenue growth, with new launches and the Hypercon acquisition expanding future opportunities. Minimal impact is expected from IRA price negotiations, and durable IP protection supports long-term royalty streams.
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
SAN DIEGO , Nov. 25, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host in...
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP ...
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
SAN DIEGO and UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Nov. 17, 2025 /PRNewswire/ -- Merus N.V.
The Big 3: OKLO, HALO, V
Mike Shorr with @ProsperTradingAcademy is mostly bullish on today's Big 3. He expects explosive price action to happen after Oklo Inc.'s (OKLO) earnings on Tuesday and sees Halozyme Therapeutics (HALO...
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that ...